Relmada Therapeutics Reports 12-Month Phase 2 Interim Data for NDV-01 in Non-Muscle Invasive Bladder Cancer
· relmada therapeutics
AI Briefing
- Relmada Therapeutics reports interim data from Phase 2 trial for NDV-01 in non-muscle invasive bladder cancer.
- The trial is evaluating NDV-01 in patients with high-risk non-muscle invasive bladder cancer.
- Results to be presented at an upcoming medical conference.
Advertisement